Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial chaperone BCS1 (BCS1L) is an essential assembly factor located in the inner mitochondrial membrane, belonging to the AAA+ ATPase family. It plays a critical role in the final steps of mitochondrial respiratory chain complex III (ubiquinol-cytochrome c reductase) assembly by facilitating the insertion of the catalytic Rieske iron-sulfur protein, thereby enabling full enzyme functionality and efficient ATP synthesis through oxidative phosphorylation. Mutations in BCS1L disrupt this process, causing varied mitochondrial diseases—including severe multisystem disorders (GRACILE syndrome) and milder conditions with sensorineural hearing loss (Björnstad syndrome)—characterized by reduced complex III activity, impaired energy production, and multi-organ impairment. BCS1L’s disease spectrum is wide, as its deficiency affects not only ATP synthesis but also leads to oxidative stress and altered iron metabolism, with pathogenic mutations serving as biomarkers for clinical diagnosis[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial chaperone BCS1 (BCS1L).